Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: CareDx Inc., 3 years.
Chief executive roles
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 7, 2025 | CareDx Inc. | Open-market sale | −10,000 | $18.58 | $185,800 |
| Jun 17, 2025 | CareDx Inc. | Open-market sale | −10,000 | $19.24 | $192,400 |
| Jun 13, 2025 | CareDx Inc. | Grant or award | +12,103 | — | — |
| Apr 30, 2025 | CareDx Inc. | Open-market sale | −13,281 | $17.23 | $228,832 |
| Nov 26, 2024 | CareDx Inc. | Option exercise | +5,000 | $12.24 | $61,200 |
| Nov 26, 2024 | CareDx Inc. | Open-market sale | −5,000 | $25.00 | $125,000 |
| Aug 20, 2024 | CareDx Inc. | Option exercise | +26,708 | $7.96 | $212,596 |
| Aug 20, 2024 | CareDx Inc. | Open-market sale | −8,844 | $33.23 | $293,886 |
| Aug 20, 2024 | CareDx Inc. | Open-market sale | −13,890 | $33.25 | $461,843 |
| Aug 20, 2024 | CareDx Inc. | Open-market sale | −12,818 | $32.67 | $418,764 |
| Jul 8, 2024 | CareDx Inc. | Grant or award | +1,034 | — | — |
| Jun 14, 2024 | CareDx Inc. | Grant or award | +10,570 | — | — |
| Apr 29, 2024 | CareDx Inc. | Option exercise | +13,281 | $5.27 | $69,991 |
| Apr 4, 2024 | CareDx Inc. | Grant or award | +1,249 | — | — |
| Jan 4, 2024 | CareDx Inc. | Grant or award | +1,525 | — | — |
Questions about Peter Maag
What boards is Peter Maag on?
Peter Maag sits on the boards of CareDx Inc. and Kyverna Therapeutics Inc.
Has Peter Maag been a CEO?
Yes — Peter Maag was CEO of Kyverna Therapeutics Inc. (2024 – 2024).
How long has Peter Maag served on boards?
Our records show at least 7 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.